Suzanne Bruhn
Direktor/Vorstandsmitglied bei MIND MEDICINE (MINDMED) INC.
Vermögen: 698 313 $ am 31.05.2024
Profil
Suzanne Louise Bruhn is currently the President, Chief Executive Officer & Director at Tiaki Therapeutics, Inc. She is also the Chief Executive Officer at Charcot-Marie-Tooth Association.
In addition, she holds the position of Director at EMPath.
Dr. Bruhn is an Independent Director at Travere Therapeutics, Inc., Pliant Therapeutics, Inc., Mind Medicine (MindMed), Inc., and Vigil Neuroscience, Inc. In her former positions, Dr. Bruhn served as the President, Chief Executive Officer & Director at Proclara Biosciences, Inc. from 2017 to 2018.
She also held the same positions at Promedior, Inc. from 2012 to 2015.
Additionally, she was an Independent Director at Spyre Therapeutics, Inc. from 2017 to 2020.
Dr. Bruhn served as a Director at Raptor Pharmaceuticals Corp.
and Horizon Pharmaceutical LLC from 2011 to 2016.
She was also an Independent Director at Avalo Therapeutics, Inc. from 2020 to 2021 and at Novelion Therapeutics, Inc. from 2017 to 2020.
Prior to these roles, she held the position of SVP-Strategic Planning & Program Management at Shire Plc and Shire Human Genetic Therapies, Inc. from 1998 to 2012.
Dr. Bruhn completed her undergraduate degree at Iowa State University and holds a doctorate from the Massachusetts Institute of Technology.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 19.04.2024 | 35 081 ( 0,06% ) | 425 533 $ | 31.05.2024 | |
| 08.05.2024 | 22 250 ( 0,03% ) | 165 095 $ | 31.05.2024 | |
| 10.06.2024 | 12 237 ( 0,02% ) | 107 686 $ | 31.05.2024 | |
VIGIL NEUROSCIENCE, INC.
-.--% | 05.06.2024 | 0 ( -.--% ) | - $ | 31.05.2024 |
Aktive Positionen von Suzanne Bruhn
| Unternehmen | Position | Beginn |
|---|---|---|
| PLIANT THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.07.2016 |
| TRAVERE THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 08.04.2020 |
| VIGIL NEUROSCIENCE, INC. | Direktor/Vorstandsmitglied | 27.07.2022 |
| MIND MEDICINE (MINDMED) INC. | Direktor/Vorstandsmitglied | 11.08.2022 |
EMPath
 EMPath Miscellaneous Commercial ServicesCommercial Services EMPath provides nonprofit programs for women. The non-profit company is based in Boston, MA. | Direktor/Vorstandsmitglied | - |
Charcot-Marie-Tooth Association
 Charcot-Marie-Tooth Association Miscellaneous Commercial ServicesCommercial Services The Charcot-Marie-Tooth Association operates as a non-profit organization. The private company is based in Glenolden, PA. Suzanne Louise Bruhn has been the CEO of the company since 2023. | Vorstandsvorsitzender | 01.11.2023 |
Ehemalige bekannte Positionen von Suzanne Bruhn
| Unternehmen | Position | Ende |
|---|---|---|
| AVALO THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 10.11.2021 |
| SPYRE THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.08.2020 |
| NOVELION THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 16.01.2020 |
| ░░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Suzanne Bruhn
| Iowa State University | Undergraduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 6 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| AVALO THERAPEUTICS, INC. | Health Technology |
| TRAVERE THERAPEUTICS, INC. | Health Technology |
| PLIANT THERAPEUTICS, INC. | Health Technology |
| MIND MEDICINE (MINDMED) INC. | Health Technology |
| VIGIL NEUROSCIENCE, INC. | Health Technology |
| Private Unternehmen | 10 |
|---|---|
Proclara Biosciences, Inc.
 Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | Health Technology |
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Raptor Pharmaceuticals Corp.
 Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Health Technology |
EMPath
EMPath Miscellaneous Commercial ServicesCommercial Services EMPath provides nonprofit programs for women. The non-profit company is based in Boston, MA. | Commercial Services |
Promedior, Inc.
 Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | Health Technology |
Shire Human Genetic Therapies, Inc.
 Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Health Technology |
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
Novelion Therapeutics, Inc.
 Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelion Therapeutics, Inc. engaged in the development and commercialization of pharmaceuitical products. It focused in providing new standards of care for individuals living with rare diseases. The company was founded on February 3, 1981 and was headquartered in Vancouver, Canada. | Health Technology |
Tiaki Therapeutics, Inc.
 Tiaki Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tiaki Therapeutics, Inc. develops novel therapeutics for Alzheimer's disease. The company was founded by Barbara Tate and is headquartered in Cambridge, MA. | Commercial Services |
Charcot-Marie-Tooth Association
Charcot-Marie-Tooth Association Miscellaneous Commercial ServicesCommercial Services The Charcot-Marie-Tooth Association operates as a non-profit organization. The private company is based in Glenolden, PA. Suzanne Louise Bruhn has been the CEO of the company since 2023. | Commercial Services |
